Arthritis treatment
Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.
1. A method for treating inflammation of the eye caused by arthritis in a human subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-IL-1α antibody that binds IL1-a with the K a of at least 1×10 9 M −1 to treat the inflammation of the eye in the subject, wherein the inflammation in the eye of the human subject is completely resolved following administration of the anti-IL-1α antibody.
2. The method of claim 1 , wherein the inflammation of the eye is uveitis.
3. The method of claim 1 , wherein the treatment reduces pain in the eye.
4. The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody.
5. The method of claim 4 , wherein the monoclonal antibody is an IgG1.
6. The method of claim 4 , wherein the monoclonal antibody comprises all of the complementarity determining regions of MABp1.
7. The method of claim 4 , wherein the monoclonal antibody is MABp1.
8. The method of claim 1 , wherein the pharmaceutical composition is administered to the eye topically.
9. The method of claim 1 , wherein the pharmaceutical composition is administered to the eye by injection.